Oral Abstract: CML-593 the Novel BCR::ABL1 Allosteric Inhibitor HS-10382/TERN-701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (tkis) and Acts Synergistically with TKIs in BCR::ABL1+ Cancer Cell Lines
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
CML,chronic myeloid leukemia,tyrosine kinase inhibitors,allosteric inhibition
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要